Shell Asset Management Co. held its stake in OraSure Technologies, Inc. (NASDAQ:OSUR) during the second quarter, according to its most recent filing with the SEC. The fund owned 58,419 shares of the medical instruments supplier’s stock at the end of the second quarter. Shell Asset Management Co. owned 0.10% of OraSure Technologies worth $1,008,000 as of its most recent SEC filing.
Several other large investors have also recently bought and sold shares of the stock. Campbell & CO Investment Adviser LLC increased its stake in OraSure Technologies by 38.5% in the second quarter. Campbell & CO Investment Adviser LLC now owns 26,155 shares of the medical instruments supplier’s stock valued at $451,000 after buying an additional 7,265 shares during the last quarter. Hartford Investment Management Co. purchased a new stake in OraSure Technologies during the second quarter valued at $318,000. Acadian Asset Management LLC increased its stake in OraSure Technologies by 32.5% in the second quarter. Acadian Asset Management LLC now owns 1,846,854 shares of the medical instruments supplier’s stock valued at $31,877,000 after buying an additional 452,642 shares during the last quarter. Russell Investments Group Ltd. increased its stake in OraSure Technologies by 133.0% in the second quarter. Russell Investments Group Ltd. now owns 497,926 shares of the medical instruments supplier’s stock valued at $8,594,000 after buying an additional 284,259 shares during the last quarter. Finally, Louisiana State Employees Retirement System increased its stake in OraSure Technologies by 5.9% in the second quarter. Louisiana State Employees Retirement System now owns 23,500 shares of the medical instruments supplier’s stock valued at $406,000 after buying an additional 1,300 shares during the last quarter. 89.76% of the stock is owned by institutional investors and hedge funds.
Shares of OraSure Technologies, Inc. (OSUR) traded up 1.45% during midday trading on Friday, hitting $20.26. The company had a trading volume of 863,698 shares. The company has a market cap of $1.20 billion, a price-to-earnings ratio of 37.45 and a beta of 1.57. OraSure Technologies, Inc. has a 12 month low of $6.87 and a 12 month high of $21.59. The stock’s 50-day moving average price is $18.98 and its 200-day moving average price is $14.50.
OraSure Technologies (NASDAQ:OSUR) last issued its quarterly earnings data on Wednesday, August 2nd. The medical instruments supplier reported $0.09 EPS for the quarter, topping the Zacks’ consensus estimate of $0.07 by $0.02. The firm had revenue of $40.18 million during the quarter, compared to the consensus estimate of $36.54 million. OraSure Technologies had a return on equity of 15.64% and a net margin of 22.29%. The firm’s revenue was up 28.1% on a year-over-year basis. During the same period in the prior year, the business earned $0.07 EPS. On average, equities research analysts forecast that OraSure Technologies, Inc. will post $0.48 EPS for the current year.
Several equities research analysts have recently weighed in on the company. Canaccord Genuity increased their price objective on OraSure Technologies from $21.00 to $22.00 and gave the company a “buy” rating in a report on Thursday, August 3rd. BidaskClub downgraded OraSure Technologies from a “buy” rating to a “hold” rating in a report on Monday, July 31st. Stephens reaffirmed an “overweight” rating and set a $19.00 price target (up from $14.00) on shares of OraSure Technologies in a report on Tuesday, July 11th. Jefferies Group LLC increased their price target on OraSure Technologies from $16.00 to $19.00 and gave the stock a “buy” rating in a report on Wednesday, June 28th. Finally, Zacks Investment Research raised OraSure Technologies from a “hold” rating to a “buy” rating and set a $18.00 price target for the company in a report on Saturday, May 6th. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. OraSure Technologies presently has a consensus rating of “Buy” and a consensus target price of $15.46.
In related news, CEO Douglas A. Michels sold 290,495 shares of the company’s stock in a transaction on Tuesday, June 27th. The stock was sold at an average price of $16.75, for a total transaction of $4,865,791.25. Following the completion of the transaction, the chief executive officer now directly owns 894,012 shares in the company, valued at approximately $14,974,701. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, EVP Anthony Zezzo II sold 72,916 shares of the business’s stock in a transaction on Monday, August 7th. The stock was sold at an average price of $21.26, for a total value of $1,550,194.16. Following the transaction, the executive vice president now owns 218,326 shares of the company’s stock, valued at approximately $4,641,610.76. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 1,036,670 shares of company stock valued at $19,807,152. 7.80% of the stock is owned by company insiders.
About OraSure Technologies
OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.
Receive News & Ratings for OraSure Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.